Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accumulated Expenses (2021 - 2025)

InMed Pharmaceuticals' Accumulated Expenses history spans 5 years, with the latest figure at $65869.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 80.47% year-over-year to $65869.0; the TTM value through Dec 2025 reached $65869.0, down 80.47%, while the annual FY2025 figure was $73143.0, 69.78% down from the prior year.
  • Accumulated Expenses reached $65869.0 in Q4 2025 per INM's latest filing, down from $111662.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $542305.0 in Q2 2023 to a low of $54629.0 in Q1 2024.
  • Average Accumulated Expenses over 5 years is $209208.8, with a median of $137552.0 recorded in 2021.
  • The largest YoY upside for Accumulated Expenses was 750.58% in 2025 against a maximum downside of 80.47% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $382114.0 in 2021, then tumbled by 63.59% to $139120.0 in 2022, then dropped by 27.8% to $100446.0 in 2023, then surged by 235.74% to $337236.0 in 2024, then plummeted by 80.47% to $65869.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Accumulated Expenses are $65869.0 (Q4 2025), $111662.0 (Q3 2025), and $73143.0 (Q2 2025).